Indications, diagnostic tests and Helicobacter pylori eradication therapy. Recommendations by the 2nd Spanish Consensus Conference.

The results of the 2nd Spanish Consensus Conference for appropriate practice regarding indications for eradication, diagnostic tests, and therapy regimens for Helicobacter pylori infection are summarized. The Conference was based on literature searches in Medline, abstracts from three international meetings, and abstracts from national meetings. Results were agreed upon and approved by the whole group. Results are supplemented by evidence grades and recommendation levels according to the classification used in the Clinical Practice Guidelines issued by Cochrane Collaboration. Convincing indications (peptic ulcer, duodenal erosions with no history of ASA or NSAIDs, MALT lymphoma), and not so convincing indications (functional dyspepsia, patients receiving low-dose ASA for platelet aggregation, gastrectomy stump in patients operated on for gastric cancer, first-degree relatives of patients with gastric cancer, lymphocytic gastritis, and Ménétrier s disease) for H. pylori eradication are discussed. Diagnostic recommendations for various clinical conditions (peptic ulcer, digestive hemorrhage secondary to ulcer, eradication control, patients currently or recently receiving antibiotic or antisecretory therapy), as well as diagnostic tests requiring biopsy collection (histology, urease fast test, and culture) when endoscopy is needed for clinical diagnosis, and non-invasive tests requiring no biopsy collection (13C-urea breath test, serologic tests, and fecal antigen tests) when endoscopy is not needed are also discussed. As regards treatment, first-choice therapies (triple therapy using a PPI and two antibiotics), therapy length, quadruple therapy, and a number of novel antibiotic options as "rescue" therapy are prioritized, the fact that prolonging PPI therapy following effective eradication is unnecessary for patients with duodenal ulcer but not for all gastric ulcers is documented, the fact that cultures and antibiograms are not needed for all eradicating therapies is indicated, and finally the test and treat strategy is considered adequate, however only under certain circumstances.

[1]  D. Forman,et al.  Initial management strategies for dyspepsia. , 2009, The Cochrane database of systematic reviews.

[2]  J. Gisbert,et al.  ¿Siete o diez días? Estudio de coste-efectividad sobre la duración del tratamiento de la infección por H. pylori en atención primaria , 2006 .

[3]  F. Mégraud,et al.  Diagnosis of Helicobacter pylori Infection , 2006, Helicobacter.

[4]  N. Talley American Gastroenterological Association medical position statement: evaluation of dyspepsia. , 2005, Gastroenterology.

[5]  J. Gisbert,et al.  Helicobacter pylori“Rescue” Therapy After Failure of Two Eradication Treatments , 2005, Helicobacter.

[6]  A. Montserrat,et al.  Seven versus Ten Days of Rabeprazole Triple Therapy for Helicobacter pylori Eradication: A Multicenter Randomized Trial , 2005, The American Journal of Gastroenterology.

[7]  J. Gisbert,et al.  Systematic Review and Meta‐analysis: Proton Pump Inhibitor vs. Ranitidine Bismuth Citrate Plus Two Antibiotics in Helicobacter pylori Eradication , 2005, Helicobacter.

[8]  J. Gisbert,et al.  Systematic review and meta‐analysis: is 1‐week proton pump inhibitor‐based triple therapy sufficient to heal peptic ulcer? , 2005, Alimentary pharmacology & therapeutics.

[9]  X. Calvet,et al.  Comparison of Two Management Strategies for Helicobacter pylori Treatment: Clinical Study and Cost‐effectiveness Analysis , 2005, Helicobacter.

[10]  P. Malfertheiner,et al.  Breath and string test: a diagnostic package for the identification of treatment failure and antibiotic resistance of Helicobacter pylori without the necessity of upper gastrointestinal endoscopy. , 2005, World journal of gastroenterology.

[11]  J. Hallas,et al.  Helicobacter pylori test and eradicate versus prompt endoscopy for management of dyspeptic patients: 6.7 year follow up of a randomised trial , 2004, Gut.

[12]  L. Fischbach,et al.  Meta‐analysis: the efficacy, adverse events, and adherence related to first‐line anti‐Helicobacter pylori quadruple therapies , 2004, Alimentary pharmacology & therapeutics.

[13]  J. Gisbert,et al.  Review article: 13C‐urea breath test in the diagnosis of Helicobacter pylori infection – a critical review , 2004, Alimentary pharmacology & therapeutics.

[14]  Y. Niv,et al.  13C-Urea Breath Test for Diagnosis of Helicobacter pylori Infection in the Elderly , 2004, Digestive Diseases and Sciences.

[15]  J. Gisbert,et al.  Stool Antigen Test for the Diagnosis of Helicobacter pylori Infection: a Systematic Review , 2004, Helicobacter.

[16]  D. Sánchez-Muñoz,et al.  Diagnosis of Helicobacter pylori infection in patients with bleeding ulcer disease: rapid urease test and histology. , 2004, Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.

[17]  J. Gisbert,et al.  Helicobacter pylori eradication therapy vs. antisecretory non‐eradication therapy (with or without long‐term maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer , 2004 .

[18]  M. Rugge,et al.  Non-invasive diagnosis of Helicobacter pylori infection: simplified 13C-urea breath test, stool antigen testing, or DNA PCR in human feces in a clinical laboratory setting? , 2004, Clinical biochemistry.

[19]  J. Gisbert,et al.  Esomeprazole-based therapy in Helicobacter pylori eradication: a meta-analysis. , 2004, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[20]  J. Gisbert,et al.  Helicobacter pylori eradication therapy vs. antisecretory non‐eradication therapy for the prevention of recurrent bleeding from peptic ulcer , 2004 .

[21]  J. Gisbert,et al.  The TETRA Study: A prospective evaluation of Helicobacter pylori‘Test‐and‐Treat’ Strategy on 736 Patients in Clinical Practice , 2004, Helicobacter.

[22]  M. Färkkilä,et al.  Does the ‘test‐and‐treat’ strategy work in primary health care for management of uninvestigated dyspepsia? A prospective two‐year follow‐up study of 1552 patients , 2004, Scandinavian journal of gastroenterology.

[23]  J. Gisbert,et al.  Pantoprazole based therapies in Helicobacter pylori eradication: a systematic review and meta-analysis , 2004, European journal of gastroenterology & hepatology.

[24]  M. Stolte,et al.  Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series , 2003, Gut.

[25]  T. Burke,et al.  Incidence of outpatient physician claims for upper gastrointestinal symptoms among new users of celecoxib, ibuprofen, and naproxen in an insured population in the United States , 2003, American Journal of Gastroenterology.

[26]  X. Bonfill,et al.  Guía de práctica clínica sobre el manejo del paciente con dispepsia , 2003 .

[27]  Sheng-Nan Lu,et al.  One-week low-dose triple therapy without anti-acid treatment has sufficient efficacy on Helicobacter pylori eradication and ulcer healing. , 2003, Hepato-gastroenterology.

[28]  F. Gomollón,et al.  Breath test is very reliable for diagnosis of Helicobacter pylori infection in real clinical practice. , 2003, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[29]  A. Gasbarrini,et al.  Meta‐analysis: the relationship between Helicobacter pylori infection and gastro‐oesophageal reflux disease , 2003, Alimentary pharmacology & therapeutics.

[30]  J. Kleibeuker,et al.  Approach to treatment of dyspepsia in primary care: a randomized trial comparing "test-and-treat" with prompt endoscopy. , 2003, Archives of internal medicine.

[31]  F. Perna,et al.  Diagnosis and treatment of Helicobacter: a 2002 updated review , 2003, Alimentary pharmacology & therapeutics.

[32]  S. Veldhuyzen van Zanten,et al.  What are the global response rates to Helicobacter pylori eradication therapy? , 2003, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[33]  G. Manes,et al.  Empirical prescribing for dyspepsia: randomised controlled trial of test and treat versus omeprazole treatment , 2003, BMJ : British Medical Journal.

[34]  D. Graham,et al.  Meta‐analysis: proton pump inhibitor or H2‐receptor antagonist for Helicobacter pylori eradication , 2003, Alimentary pharmacology & therapeutics.

[35]  J. Gisbert,et al.  Triple vs. quadruple therapy for treating Helicobacter pylori infection: an updated meta‐analysis , 2003, Alimentary pharmacology & therapeutics.

[36]  A. Hungin,et al.  Prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease: systematic review , 2003, BMJ : British Medical Journal.

[37]  J. Gisbert,et al.  ‘Rescue’ Therapy with Rifabutin after Multiple Helicobacter pylori Treatment Failures , 2003, Helicobacter.

[38]  C. Hassan,et al.  A third-line levofloxacin-based rescue therapy for Helicobacter pylori eradication. , 2003, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[39]  X. Calvet,et al.  Rabeprazole‐based therapies in Helicobacter pylori eradication , 2003 .

[40]  W. Hui,et al.  Effect of treatment of Helicobacter pylori on the prevention of gastroduodenal ulcers in patients receiving long‐term NSAIDs: a double‐blind, placebo‐controlled trial , 2003, Alimentary pharmacology & therapeutics.

[41]  Y. Kinoshita,et al.  Influence of lansoprazole, famotidine, roxatidine and rebamipide administration on the urea breath test for the diagnosis of Helicobacter pylori infection , 2003, Journal of gastroenterology and hepatology.

[42]  J. Gisbert,et al.  Validation of the 13c-urea breath test for the initial diagnosis of helicobacter pylori infection and to confirm eradication after treatment. , 2003, Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.

[43]  K. Tominaga,et al.  Is eradication sufficient to heal gastric ulcers in patients infected with Helicobacter pylori? A randomized, controlled, prospective study , 2003, Alimentary pharmacology & therapeutics.

[44]  M. Castro-Fernández,et al.  The effectiveness of (IgG-ELISA) serology as an alternative diagnostic method for detecting Helicobacter pylori infection in patients with gastro-intestinal bleeding due to gastro-duodenal ulcer. , 2002, Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.

[45]  F. Chang,et al.  No Difference of Accuracy Between Capillary and Venous Blood in Rapid Whole Blood Test for Diagnosis of Helicobacter pylori Infection , 2002, Digestive Diseases and Sciences.

[46]  A. Chott,et al.  Endoscopic ultrasound in the follow up and response assessment of patients with primary gastric lymphoma , 2002, Gut.

[47]  J. Lindebjerg,et al.  Diagnosis of Helicobacter pylori in Bleeding Peptic Ulcer Patients, Evaluation of Urea-Based Tests , 2002, Digestion.

[48]  S. Vigneri,et al.  Stool antigen assay (HpSA) is less reliable than urea breath test for post‐treatment diagnosis of Helicobacter pylori infection , 2002, Alimentary pharmacology & therapeutics.

[49]  J. Deeks,et al.  Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials , 2002, BMJ : British Medical Journal.

[50]  P. Malfertheiner,et al.  Impact of Furazolidone‐Based Quadruple Therapy for Eradication of Helicobacter pylori after Previous Treatment Failures , 2002, Helicobacter.

[51]  W. Chey,et al.  Reappraisal of non‐invasive management strategies for uninvestigated dyspepsia: a cost‐minimization analysis , 2002, Alimentary pharmacology & therapeutics.

[52]  A. López-Sanromán,et al.  Efficacy of quadruple therapy with pantoprazole, bismuth, tetracycline and metronidazole as rescue treatment for Helicobacter pylori infection , 2002, Alimentary pharmacology & therapeutics.

[53]  J. Gisbert,et al.  Prevalencia de la infección por Helicobacter pylori en la enfermedad por reflujo gastroesofágico y en el esófago de Barrett: revisión sistemática y metaanálisis , 2002 .

[54]  R. Colin Duodenal ulcer healing with 1‐week eradication triple therapy followed, or not, by anti‐secretory treatment: a multicentre double‐blind placebo‐controlled trial , 2002, Alimentary pharmacology & therapeutics.

[55]  J. Gisbert,et al.  Helicobacter pylori ‘rescue’ regimen when proton pump inhibitor‐based triple therapies fail , 2002, Alimentary pharmacology & therapeutics.

[56]  K. Mafune,et al.  Studies of 13C-Urea Breath Test for Diagnosis of Helicobacter pylori Infection in Patients after Partial Gastrectomy , 2002, Digestion.

[57]  A. Blum,et al.  Combined analysis of the ORCHID and OCAY studies: does eradication of Helicobacter pylori lead to sustained improvement in functional dyspepsia symptoms? , 2002, Gut.

[58]  L. Murray,et al.  Randomised trial of endoscopy with testing for Helicobacter pylori compared with non-invasive H pylori testing alone in the management of dyspepsia , 2002, BMJ : British Medical Journal.

[59]  E. Grace,et al.  Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment—Helicobacter pylori positive (CADET-Hp) randomised controlled trial , 2002, BMJ : British Medical Journal.

[60]  Á. Lanas,et al.  Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low‐dose aspirin , 2002, Alimentary pharmacology & therapeutics.

[61]  J. Gisbert,et al.  Infección por Helicobacter pylori y dispepsia funcional. Metaanálisis de la eficacia del tratamiento erradicador , 2002 .

[62]  A. Mentis,et al.  Effectiveness of two quadruple, tetracycline‐ or clarithromycin‐containing, second‐line, Helicobacter pylori eradication therapies , 2002, Alimentary pharmacology & therapeutics.

[63]  J. Gisbert,et al.  Rapid urease test utility for Helicobacter pylori infection diagnosis in gastric ulcer disease. , 2002, Hepato-gastroenterology.

[64]  J. Gisbert,et al.  [Rapid whole blood test for the diagnosis of H. pylori infection. Can it be recommended for the diagnosis of the infection in clinical practice?]. , 2002, Medicina clinica.

[65]  M. F. Arjona,et al.  Calidad del esperma y concentraciones hormonales de varones con oligozoospermia antes y después del tratamiento con hormona foliculostimulante , 2002 .

[66]  L. Fischbach,et al.  Sources of variation of Helicobacter pylori treatment success in adults worldwide: a meta-analysis. , 2002, International journal of epidemiology.

[67]  P. Malfertheiner,et al.  Current concepts in the management of Helicobacter pylori infection—The Maastricht 2‐2000 Consensus Report , 2002, Alimentary pharmacology & therapeutics.

[68]  Z. Tulassay,et al.  One week of treatment with esomeprazole-based triple therapy eradicates Helicobacter pylori and heals patients with duodenal ulcer disease , 2001, European journal of gastroenterology & hepatology.

[69]  P. Malfertheiner,et al.  A meta‐analysis comparing eradication, healing and relapse rates in patients with Helicobacter pylori‐associated gastric or duodenal ulcer , 2001, Alimentary pharmacology & therapeutics.

[70]  J. Gisbert,et al.  Helicobacter pylori eradication therapy is more effective in peptic ulcer than in non-ulcer dyspepsia , 2001, European journal of gastroenterology & hepatology.

[71]  G. Tytgat,et al.  Should anti-Helicobacter therapy be different in patients with dyspepsia compared with patients with peptic ulcer diathesis? , 2001, European journal of gastroenterology & hepatology.

[72]  J. Gisbert,et al.  Helicobacter pylori Therapy: First-Line Options and Rescue Regimen , 2001, Digestive Diseases.

[73]  I. Beales Efficacy of Helicobacter pylori eradication therapies: a single centre observational study , 2001, BMC gastroenterology.

[74]  C. Hassan,et al.  A triple therapy regimen after failed Helicobacter pylori treatments , 2001, Alimentary pharmacology & therapeutics.

[75]  M. Gubina,et al.  Is a one‐week course of triple anti‐Helicobacter pylori therapy sufficient to control active duodenal ulcer? , 2001, Alimentary pharmacology & therapeutics.

[76]  F. Gomollón,et al.  Fracaso de la serología rápida para Helicobacter pylori como método diagnóstico en la consulta de atención primaria , 2001 .

[77]  D. Forman,et al.  Initial management strategies for dyspepsia. , 2001, The Cochrane database of systematic reviews.

[78]  J. Gisbert,et al.  Are twelve days of omeprazole, amoxicillin and clarithromycin better than six days for treating H. pylori infection in peptic ulcer and in non-ulcer dyspepsia? , 2001, Hepato-gastroenterology.

[79]  G. Baxter,et al.  Benefit of Helicobacter pylori eradication in the treatment of ulcer-like dyspepsia in primary care , 2001 .

[80]  F. Chan,et al.  Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. , 2001, The New England journal of medicine.

[81]  L. Laine,et al.  Therapy for Helicobacter pylori in Patients with Nonulcer Dyspepsia , 2001, Annals of Internal Medicine.

[82]  M. Stolte,et al.  Diagnostic Accuracy of 13C-Urea Breath Test in the Diagnosis of Helicobacter pylori Infection in Patients with Partial Gastric Resection due to Peptic Ulcer Disease , 2001, Digestion.

[83]  G. Manes,et al.  Accuracy of the stool antigen test in the diagnosis of Helicobacter pylori infection before treatment and in patients on omeprazole therapy , 2001, Alimentary pharmacology & therapeutics.

[84]  A. Andriulli,et al.  Randomized study of two “rescue” therapies for helicobacter pylori-infected patients after failure of standard triple therapies , 2001, American Journal of Gastroenterology.

[85]  A. Gasbarrini,et al.  Rifabutin‐based Helicobacter pylori eradication ‘rescue therapy’ , 2001, Alimentary pharmacology & therapeutics.

[86]  B. Marshall,et al.  Accurate diagnosis of Helicobacter pylori. Urease tests. , 2000, Gastroenterology clinics of North America.

[87]  S. Berardi,et al.  Accurate diagnosis of Helicobacter pylori. Stool tests. , 2000, Gastroenterology clinics of North America.

[88]  D. Graham,et al.  Accurate diagnosis of Helicobacter pylori. 13C-urea breath test. , 2000, Gastroenterology clinics of North America.

[89]  F. Gomollón,et al.  Alto índice de erradicación de Helicobacter pylori en pacientes con úlcera duodenal tras fracaso de un tratamiento previo , 2000 .

[90]  J. B. Díez,et al.  Eficacia de una terapia secuencial en la erradicación de Helicobacter pylori: cuádruple terapia con omeprazol, metronidazol, tetraciclina y bismuto tras el fracaso de la combinación de omeprazol, claritromicina y amoxicilina , 2000 .

[91]  N. Lehn,et al.  Rifabutin-based Triple Therapy After Failure of Helicobacter pylori Eradication Treatment: Preliminary Experience , 2000, Journal of clinical gastroenterology.

[92]  J. Gisbert,et al.  Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta‐analysis of eradication of Helicobacter pylori , 2000, Alimentary pharmacology & therapeutics.

[93]  E. Quigley,et al.  Latin-American Consensus Conference on Helicobacter pylori infection , 2000, American Journal of Gastroenterology.

[94]  E. Quigley,et al.  Latin-American Consensus Conference on Helicobacter pylori infection 1 1 A list of delegates to the , 2000 .

[95]  F. Fernández-Bañares,et al.  Accuracy of an enzyme immunoassay for the detection of Helicobacter pylori in stool specimens in the diagnosis of infection and posttreatment check-up , 2000, American Journal of Gastroenterology.

[96]  Gabriel,et al.  Helicobacter pylori eradication: proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics for 1 week—a meta‐analysis of efficacy , 2000, Alimentary pharmacology & therapeutics.

[97]  Annmarie Touborg Lassen,et al.  Helicobacter pylori test-and-eradicate versus prompt endoscopy for management of dyspeptic patients: a randomised trial , 2000, The Lancet.

[98]  K. Lai,et al.  Ulcer‐healing drugs are required after eradication of Helicobacter pylori in patients with gastric ulcer but not duodenal ulcer haemorrhage , 2000, Alimentary pharmacology & therapeutics.

[99]  Michopoulos,et al.  Randomized study comparing omeprazole with ranitidine as anti‐secretory agents combined in quadruple second‐line Helicobacter pylori eradication regimens , 2000, Alimentary pharmacology & therapeutics.

[100]  L. Laine,et al.  Endoscopic biopsy requirements for post-treatment diagnosis of Helicobacter pylori. , 2000, Gastrointestinal endoscopy.

[101]  C. O'Morain,et al.  Rapid urease tests lack sensitivity in Helicobacter pylori diagnosis when peptic ulcer disease presents with bleeding , 2000, American Journal of Gastroenterology.

[102]  J. Gisbert,et al.  Proton pump inhibitor versus ranitidine bismuth citrate plus two antibiotics for one week. A meta-analysis of its efficacy on Hericobacter pylori eradication , 2000 .

[103]  A. Gasbarrini,et al.  Efficacy of different Helicobacter pylori eradication regimens in patients affected by insulin-dependent diabetes mellitus. , 2000, Scandinavian journal of gastroenterology.

[104]  Clemente,et al.  Rifabutin‐based ‘rescue therapy’ for Helicobacter pylori infected patients after failure of standard regimens , 2000, Alimentary pharmacology & therapeutics.

[105]  F. Gomollón,et al.  Quadruple Therapy Is Effective for Eradicating Helicobacter pylori After Failure of Triple Proton‐Pump Inhibitor–Based Therapy: A Detailed, Prospective Analysis of 21 Consecutive Cases , 1999, Helicobacter.

[106]  Gisbert,et al.  Seven‐day ‘rescue’ therapy after Helicobacter pylori treatment failure: omeprazole, bismuth, tetracycline and metronidazole vs. ranitidine bismuth citrate, tetracycline and metronidazole , 1999, Alimentary pharmacology & therapeutics.

[107]  J. Gisbert,et al.  Re-treatment after Helicobacter pylori eradication failure. , 1999, European journal of gastroenterology & hepatology.

[108]  R. Newcombe,et al.  A comparison of two rapid whole-blood tests and laboratory serology, in the diagnosis of Helicobacter pylori infection. , 1999, European journal of gastroenterology & hepatology.

[109]  P. Malfertheiner,et al.  Validity of a modified 13C-urea breath test for pre- and posttreatment diagnosis of Helicobacter pylori infection in the routine clinical setting , 1999, American Journal of Gastroenterology.

[110]  L. Lundell,et al.  Lack of effect of acid suppression therapy on gastric atrophy. Nordic Gerd Study Group. , 1999, Gastroenterology.

[111]  K. Bamford,et al.  A prospective randomised trial of a “test and treat” policy versus endoscopy based management in youngHelicobacter pylori positive patients with ulcer-like dyspepsia, referred to a hospital clinic , 1999, Gut.

[112]  P. Malfertheiner,et al.  Diagnosis of Helicobacter pylori infection with a new non-in vasive antigen-based assay , 1999, The Lancet.

[113]  J. Gisbert,et al.  Helicobacter pylori test-and-treat' strategy for dyspeptic patients. , 1999, Scandinavian journal of gastroenterology.

[114]  H. Straatman,et al.  Evaluation of treatment regimens to cure Helicobacter pylori infection—a meta‐analysis , 1999, Alimentary pharmacology & therapeutics.

[115]  E. Bayerdörffer,et al.  Rifampin and Rifabutin Resistance Mechanism inHelicobacter pylori , 1999, Antimicrobial Agents and Chemotherapy.

[116]  R. Hunt,et al.  The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta‐analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole , 1999, Alimentary pharmacology & therapeutics.

[117]  R. Hunt,et al.  Canadian Helicobacter pylori Consensus Conference update: infections in adults. Canadian Helicobacter Study Group. , 1999, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[118]  Hyde,et al.  Treatment options for Helicobacter pylori infection when proton pump inhibitor‐based triple therapy fails in clinical practice , 1999, Alimentary pharmacology & therapeutics.

[119]  Francesco,et al.  Helicobacter pylori eradication with proton pump inhibitor‐based triple therapies and re‐treatment with ranitidine bismuth citrate‐based triple therapy , 1999, Alimentary pharmacology & therapeutics.

[120]  R. Hunt,et al.  Guidelines for the management of Helicobacter pylori infection , 1998, American Journal of Gastroenterology.

[121]  J. Gisbert,et al.  Tratamiento previo con omeprazol y H. pylori: ¿disminuye la eficacia erradicadora de las «nuevas» terapias triples de una semana de duración? , 1998 .

[122]  J. Thomas 13C urea breath test , 1998, Gut.

[123]  Yung,et al.  One‐week use of ranitidine bismuth citrate, amoxycillin and clarithromycin for the treatment of Helicobacter pylori‐related duodenal ulcer , 1998, Alimentary pharmacology & therapeutics.

[124]  J. Lambert,et al.  The impact of Helicobacter pylori eradication on peptic ulcer healing , 1998, American Journal of Gastroenterology.

[125]  S. Lam,et al.  Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection , 1998, Journal of gastroenterology and hepatology.

[126]  J. Gisbert,et al.  Unhealed duodenal ulcers despite Helicobacter pylori eradication. , 1997, Scandinavian journal of gastroenterology.

[127]  G. delle Fave,et al.  Does pretreatment with omeprazole decrease the chance of eradication of Helicobacter pylori in peptic ulcer patients? , 1997, The American journal of gastroenterology.

[128]  J. Labenz,et al.  One‐week low‐dose triple therapy for Helicobacter pylori is sufficient for relief from symptoms and healing of duodenal ulcers , 1997, Alimentary pharmacology & therapeutics.

[129]  E. Kuipers,et al.  Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. , 1996, The New England journal of medicine.

[130]  G. Bianchi,et al.  Triple therapy with azithromycin, omeprazole, and amoxicillin is highly effective in the eradication of Helicobacter pylori: a controlled trial versus omeprazole plus amoxicillin. , 1996, The American journal of gastroenterology.

[131]  Robert S. Pinals,et al.  A double‐blind, placebo‐controlled trial , 1986 .

[132]  J. Lee,et al.  (Helicobacter pylori Eradication to Prevent Gastric Cancer in a High-Risk Region of China.) , 2004 .

[133]  M. Artés,et al.  Quality of Life in Functional Dyspepsia , 2004, Digestive Diseases and Sciences.

[134]  J. Gisbert,et al.  Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta‐analysis , 2003, Alimentary pharmacology & therapeutics.

[135]  L. Marzio,et al.  Triple therapy for 7 days vs. triple therapy for 7 days plus omeprazole for 21 days in treatment of active duodenal ulcer with Helicobacter pylori infection. A double blind placebo controlled trial. , 2003, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[136]  F. Gomollón,et al.  [Failure of rapid serology for Helicobacter pylori as diagnostic method in primary care consultation]. , 2001, Atencion primaria.

[137]  M. Stolte,et al.  Diagnostic accuracy of (13)C-urea breath test in the diagnosis of Helicobacter pylori infection in patients with partial gastric resection due to peptic ulcer disease: a prospective multicenter study. , 2001, Digestion.

[138]  L. Murray,et al.  Increased prevalence of precancerous changes in relatives of gastric cancer patients: critical role of H. pylori. , 2000, Gastroenterology.

[139]  J. Xiol Tratamiento de la dispepsia funcional , 2000 .

[140]  M. Stolte,et al.  Lack of effect of acid suppression therapy on gastric atrophy. , 2000, Gastroenterology.

[141]  J. Gisbert,et al.  Tratamiento erradicador de Helicobacter pylori. Recomendaciones de la II Conferencia Española de Consenso , 2000 .

[142]  J. Gisbert,et al.  HELICOBACTER PYLORI Y DISPEPSIA NO ULCEROSA : UNA ASIGNATURA PENDIENTE , 1998 .

[143]  N. Talley Quality of life in functional dyspepsia. , 1996, Scandinavian journal of gastroenterology. Supplement.